Glucose-6-phosphate dehydrogenase (G6PD) Deficiency and COVID-19.

Ariel IsraelMatitiahu BerkovitchEugene MerzonAvivit Golan-CohenIlan GreenEytan RuppinShlomo VinkerEli Magen

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

In this cohort study conducted in a national healthcare organization in Israel, we found that individuals with Glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased risk of COVID-19 infection and severity, with higher rates of hospitalization and diagnosed long COVID.

Keyphrases

coronavirus disease
sars cov
healthcare
blood glucose
replacement therapy
blood pressure
adipose tissue